Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Small airways dysfunction in systemic sclerosis. A controlled study.

C Kostopoulos1, A Rassidakis, P P Sfikakis

  • 1Department of Clinical Therapeutics, Alexandra Hospital, Athens University Medical School, Greece.

Chest
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disease-related and psychosocial factors associated with difficult-to-manage and treatment-refractory axial spondyloarthritis: insights from the Greek AxSpA Registry.

Rheumatology international·2026
Same author

Antisynthetase syndrome with predominant lung involvement. An easy to miss diagnosis.

Pulmonology·2023
Same author

Adamantiades-Behçet's disease (Behçet's disease) and COVID-19.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients.

Seminars in arthritis and rheumatism·2020
Same author

Nocebo phenomena may be enhanced in aging: Implications for clinical practice.

Maturitas·2020
Same author

Olfactory bulb and mucosa abnormalities in persistent COVID-19-induced anosmia: a magnetic resonance imaging study.

European journal of neurology·2020

Small airways dysfunction (SAD) is not a common early sign in systemic sclerosis patients who do not smoke. When SAD occurs, it does not correlate with the severity of lung disease in scleroderma.

Area of Science:

  • Pulmonary Medicine
  • Rheumatology
  • Systemic Sclerosis Research

Background:

  • Small airways disease (SAD) importance in systemic sclerosis (SSc) is debated.
  • Smoking significantly impacts SAD prevalence in SSc.
  • Need to evaluate SAD in non-smoking SSc patients.

Purpose of the Study:

  • To assess small airways dysfunction (SAD) in a cohort of non-smoking systemic sclerosis (SSc) patients.
  • To compare pulmonary function in SSc patients versus healthy controls.
  • To determine if SAD is an early or characteristic manifestation of SSc.

Main Methods:

  • Pulmonary function tests (PFTs) conducted on 31 non-smoking SSc patients and 31 matched controls.
  • Evaluated parameters included FVC, TLC, Dco, MEF25, RV, and RV/TLC.

Related Experiment Videos

  • SAD defined as MEF25 < 60% of predicted.

    • Main Results:

    • SSc patients showed significantly lower FVC, TLC, and Dco compared to controls (p < 0.05).
    • No significant difference in MEF25, RV, or RV/TLC between groups.
    • SAD prevalence was similar in SSc patients (22.6%) and controls (non-significant difference).
    • Positive correlation found between MEF25 and FEV1/FVC in SSc patients (p < 0.001).
    • No differences in clinical, demographic, or serologic features between SSc patients with and without SAD.

    Conclusions:

    • Small airways dysfunction (SAD) is not a characteristic early manifestation in non-smoking systemic sclerosis (SSc) patients.
    • The presence of SAD in SSc does not correlate with the severity of pulmonary involvement.
    • Further research may be needed to understand the role of SAD in SSc, particularly in smokers.